Claims for Patent: 10,669,245

Summary for Patent: 10,669,245

Title:	Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors
Abstract:	The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
Inventor(s):	Hans Roland LONN, Stephen Connolly, Steven Swallow, Staffan PO KARLSSON, Carl-Johan Aurell, John Fritiof PONTÉN, Kevin James Doyle, Amanda Jane VAN DE POËL, Graham Peter Jones, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John Palmer
Assignee:	Biofocus DPI Ltd , AstraZeneca AB
Application Number:	US16/358,091
Patent Claims:	1. A compound of formula (I) wherein R1 is selected from X is selected from O, S or CF2; Y is selected from O or S; Q is selected from CH or N; R6 is selected from C1-3alkyl, wherein said C1-3alkyl is optionally substituted by 1, 2 or 3 F and optionally by one substituent selected from OH, OC1-3alkyl, N(C1-3alkyl)2, cyclopropyl, or tetrahydropyran; R7 is selected from hydrogen, F, Cl or CH3; or a pharmaceutically-acceptable salt thereof. 2. The compound of claim 1, wherein R1 is X is selected from O, S or CF2; Y is selected from O or S; R6 is selected from C1-3alkyl, wherein said C1-3alkyl is optionally substituted by 1, 2 or 3 F and optionally by one substituent selected from OH, OC1-3alkyl, N(C1-3alkyl)2, cyclopropyl, or tetrahydropyran; R7 is selected from hydrogen, F, Cl or CH3; or a pharmaceutically-acceptable salt thereof. 3. The compound of claim 2, wherein R1 is X is O; R6 is C1-3alkyl, wherein said C1-3alkyl is optionally substituted by 1, 2 or 3 F; and R7 is hydrogen; or a pharmaceutically-acceptable salt thereof. 4. The compound of claim 3, wherein R1 is X is O; R6 is C1-3alkyl; and R7 is hydrogen; or a pharmaceutically-acceptable salt thereof. 5. A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier. 6. A pharmaceutical composition comprising a compound of claim 2, and a pharmaceutically acceptable adjuvant, diluent or carrier. 7. A pharmaceutical composition comprising a compound of claim 3, and a pharmaceutically acceptable adjuvant, diluent or carrier. 8. A pharmaceutical composition comprising a compound of claim 4, and a pharmaceutically acceptable adjuvant, diluent or carrier. 9. A method of treating an obstructive disease of the airway in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound of claim 1. 10. A method of treating an obstructive disease of the airway in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound of claim 2. 11. A method of treating an obstructive disease of the airway in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound of claim 3. 12. A method of treating an obstructive disease of the airway in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound of claim 4. 13. The method of claim 9, wherein the administering comprises oral administration. 14. The method of claim 10, wherein the administering comprises oral administration. 15. The method of claim 11, wherein the administering comprises oral administration. 16. The method of claim 12, wherein the administering comprises oral administration.